Akebia Therapeutics Said Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Q3 2023
Portfolio Pulse from Charles Gross
Akebia Therapeutics, Inc. (NASDAQ:AKBA) has completed a Type A meeting with the FDA regarding the resubmission of its New Drug Application (NDA) for vadadustat, a treatment for anemia due to chronic kidney disease. The company expects to resubmit the NDA in Q3 2023.
July 18, 2023 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics' successful meeting with the FDA and planned resubmission of its NDA for vadadustat could potentially boost investor confidence and positively impact the company's stock in the short term.
The successful completion of the FDA meeting and the planned resubmission of the NDA for vadadustat, a treatment for a chronic condition, could be seen as a positive development by investors. This could potentially lead to increased investor confidence and a positive impact on Akebia Therapeutics' stock in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100